APLS250117C42000
- 0.00
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Apellis Pharmaceuticals Insider Sold Shares Worth $412,296, According to a Recent SEC Filing
Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating
Insider Sale: Chief Business & Strat Officer of $APLS (APLS) Sells 1,235 Shares
Express News | RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $26 Price Target
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $31 to $47
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $32 to $60
Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.
Here's Why Apellis Pharmaceuticals (NASDAQ:APLS) Can Afford Some Debt
Apellis Pharmaceuticals Analyst Ratings
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Sector Update: Health Care Stocks Rise Late Afternoon
Positive Outlook for Apellis Pharmaceuticals Amid Strong Sales and Pipeline Advancements
Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results
Express News | Apellis Pharmaceuticals Shares Are Trading Higher After the Company Reported Preliminary Full-year 2024 U.S. Net Product Revenues of $709 Million
Apellis Pharmaceuticals Reports Strong Growth and Leadership Changes
Apellis Pharmaceuticals: COO Adam Townsend to Depart in Feb >APLS
Express News | Apellis Highlights Commercial Growth and Strategic Priorities at 43Rd Annual J.P. Morgan Healthcare Conference
Press Release: Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Buy Rating Maintained for Apellis Pharmaceuticals: Strategic Market Position and Growth Potential Justify Price Objective
Apellis Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since December 2023 -- Data Talk